Brenig Therapeutics announced on April 30, 2026, that Alexei Pushechnikov, PhD, will present their Hybrid AI drug discovery platform at the Keystone Symposia 'Computational Advances in Drug Discovery' on May 8, 2026, in London, UK.1
The poster presentation (number 1012) is titled 'The Convergence of Structural Biology and Non-Human Intelligence in Brenig Therapeutics' Early Discovery' at 12:
30 PM GMT at Park Plaza Riverbank.1
The platform, developed with Expert Systems Inc., combines physics-based structural biology and machine learning for selective, brain-penetrant small molecules, advancing programs like BT-267 (LRRK2 inhibitor for Parkinson's) and BT-409 (NLRP3 inhibitor).1
Brenig focuses on therapies for neurodegenerative, neuroinflammatory, and cardiometabolic diseases using AI/ML-enabled discovery.1
Sources:
1. https://www.prnewswire.com/news-releases/brenig-therapeutics-to-present-hybrid-ai-drug-discovery-platform-at-keystone-symposia-computational-advances-in-drug-discovery-302758584.html